Merck's HIV Push Looks Real on the Ground-But One Conference Won't Move MRK Much

Merck's HIV program looks active, but the near-term stock impact still looks limited

Merck still has a credible HIV pipeline story. Even so, conference slides alone are unlikely to drive a major move in MRK this year.

AIDS 2026 shifts the focus to once-weekly oral treatment

Last year, Merck highlighted progress in HIV prevention and treatment, including once-monthly PrEP and a once-weekly oral combination moving forward in development. For AIDS 2026, the company is emphasizing once-weekly oral treatments, with late-breaker data on islatravir plus lenacapavir and islatravir plus ulonivirine. Combined with Merck's broader pitch around once-daily, once-weekly, and once-monthly oral regimens, the program still looks active rather than symbolic.

Pipeline progress has not yet become a commercial catalyst

The investment debate is no longer whether Merck has an HIV story. It is whether that story can eventually matter financially. Until HIV contributes meaningfully to revenue or changes how the market views Merck's growth profile, conference data may improve credibility but not necessarily drive a sustained rerating.

The market is large, and convenience is the core value proposition

That pipeline interest has a real-world backdrop: nearly 40 million people worldwide were living with HIV in 2023, and 1.3 million were newly diagnosed that year. Merck is not working on a niche footnote. It is trying to build options across dosing schedules-what it has described as once-daily, once-weekly, and once-monthly oral regimens.

Less-frequent dosing matters only if it works where patients already are

For treatment, the key test is whether a simpler schedule can compete with regimens that already work. At AIDS 2026, Merck is presenting Phase 3 switch data comparing once-weekly oral islatravir plus lenacapavir with continued daily therapy in people who are already virologically-suppressed. That is the right setting: convenience only has value if it works in the patient population that actually needs it.

Resistance data remain a practical check on the strategy

Merck is also pressing important durability questions. At IAS 2025, the company highlighted data on how preexisting resistance-associated mutations in proviral DNA may affect responses to doravirine/islatravir. That matters because a less frequent dosing schedule is only compelling if the underlying regimen performs reliably in real-world patients, including those who may already carry resistance changes.

What to watch from MRK after the conference circuit

Merck still looks more like an execution story than a conference-catalyst story. The next major checkpoint is the July 26-31, 2026 AIDS 2026 meeting in Rio. After last year's once-monthly PrEP update and management's broader pitch around once-daily, once-weekly, and once-monthly oral regimens, AIDS 2026 matters as another proof point-not as evidence that the franchise is already built.

Signals that would strengthen the thesis

• Phase 3 switch data that show the once-weekly regimen is competitive in virologically-suppressed patients.
• A coherent read-through across treatment and prevention programs, rather than isolated data points.
• Evidence that convenience claims match a plausible path to broader use.

Signals that would weaken it

• Safety or virologic setbacks.
• Weakness in patients with relevant resistance background.
• A portfolio narrative that never moves beyond conference presentations.

For now, the disciplined read is neutral: Merck's HIV program looks genuine, but it still needs stronger execution and commercial relevance before investors should treat it as a near-term stock driver.